🇺🇸 FDA
Patent

US 10815285

Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases

granted A61KA61K38/00A61K48/00

Quick answer

US patent 10815285 (Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases) held by United States Government as represented by the Department of Veterans Affairs expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K38/00, A61K48/00